会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • NANOPARTICLE FOR BIOMOLECULE DELIVERY
    • 用于生物分子递送的纳米颗粒
    • WO2010139942A2
    • 2010-12-09
    • PCT/GB2010001070
    • 2010-06-01
    • UNIV STRATHCLYDEGRAHAM DUNCANWHEATE NIAL JOSEPHBROWN SARAHCRAIG GEMMA
    • GRAHAM DUNCANWHEATE NIAL JOSEPHBROWN SARAHCRAIG GEMMA
    • A61K47/48A61K41/00A61P35/00
    • A61K41/00A61K47/6923
    • A nanoparticle comprises a metal nanoparticle, e.g. gold, functionalised with at least one linker, the at least one linker comprising at least one first moiety capable of interacting with the metal nanoparticle, and at least one second moiety capable of interacting with at least one platinum group metal-based biologically active compound, e.g. a drug, wherein the molar ratio or capacity of platinum group metal-based biologically active compounds per nanoparticle is greater than (150). The present invention also relates to a method of preparing a nanoparticle according to the present invention. The present invention also relates to a biologically active nanoparticle comprising a nanoparticle according to the present invention, and at least one platinum group metal-based biologically active compound. The biologically active nanoparticle is more efficiently targeted to specific parts of the body, e.g. cancer cells, while reducing the side effects of the biomolecules being delivered.
    • 纳米颗粒包括金属纳米颗粒,例如 金,其与至少一个接头官能化,所述至少一个连接体包含至少一个能够与金属纳米颗粒相互作用的第一部分,以及至少一个能够与至少一种基于金属的金属基生物活性化合物相互作用的第二部分, 例如 一种药物,其中每个纳米颗粒的铂族金属基生物活性化合物的摩尔比或容量大于(150)。 本发明还涉及根据本发明的制备纳米颗粒的方法。 本发明还涉及包含根据本发明的纳米颗粒的生物活性纳米颗粒和至少一种基于金属的金属基生物活性化合物。 生物活性纳米颗粒更有效地靶向身体的特定部位,例如, 同时减少正在递送的生物分子的副作用。
    • 10. 发明专利
    • AT495434T
    • 2011-01-15
    • AT04768226
    • 2004-08-26
    • UNIV STRATHCLYDE
    • GRAHAM DUNCANSMITH WILLIAM EFRUK LJILJANA
    • G01N21/65C12Q1/68G01J3/44G01N33/58
    • The invention provides modified molecular beacons detectable by surface enhanced Raman spectroscopy (SERS) and related materials, processes, and methods of use. Examples methods provide for the determination of the presence or absence of a target nucleotide sequence in a sample nucleic acid by (a) providing a detection agent, which agent comprises: (i) a probe comprising a target complement sequence (TCS) being complementary to the target sequence and flanking the TCS, first and second oligonucleotide arms, said first and second oligonucleotide arms forming a stem duplex, and said first arm incorporating a first label moiety being detectable by SERS (e.g. a fluoroscein dye) and said second arm terminating in a second label moiety being detectable by SERS, which second arm further includes a surface seeking group (SSG-e.g. an azo-benzotriazole) capable of promoting association of the second label onto an enhancing surface ii) associated with said probe via said SSG, an enhancing surface, such that said first and second label moieties are in close proximity to each other and to the enhancing surface (b) exposing the sample to the detection agent, (c) detecting hybridisation of the TCS to any target sequence present in the sample by a change in the SERS spectra of said agent.